Literature DB >> 16273638

Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system.

Qiang Zhu1, Ji-Yong Liu, Hong-Wei Xu, Chong-Mei Yang, An-Zhong Zhang, Yi Cui, Hong-Bo Wang.   

Abstract

AIM: To determine the role of Fas/Fas ligand (FasL) in the immune escape of colon cancer cells.
METHODS: Immunohistochemistry was used to observe the expression of Fas and FasL in the tissues of colon cancer patients. In situ hybridization was used to detect the localization of FasL mRNA expression in cancer tissues. Terminal deoxynucleotide transferase-mediated dUTP nick end labeling (TUNEL) assay and CD45 staining were performed to detect the apoptosis of tumor-infiltrating lymphocytes (TILs). Co-culture assays of colon cancer cells (SW480) and Jurkat cells (Fas-sensitive cells) were performed to observe the counterattack of colon cancer cells to lymphocytes.
RESULTS: Of 53 cases of colon carcinomas, 23 cases (43.4%) expressed Fas which was significantly lower as compared to the normal colonic mucosa (73.3%, P<0.01), and 45 cases (84.9%) of colon carcinomas expressed FasL, whereas only two cases (3.75%) in normal mucosa expressed FasL. FasL expression in the colon cancer cells was found to be associated with increased cell death of TILs. The apoptotic rate of TIL in the FasL-positive staining regions of tumor cells was significantly higher than that in the FasL-negative staining region (54.84+/-2.79% vs 25.73+/-1.98%, P<0.01). The co-culture of SW480 cells and Jurkat cells confirmed the function of FasL on the SW480 cells. The apoptotic rates of Jurkat cells were found to be related with the amount of SW480 cells.
CONCLUSION: Colon cancer cells can escape the immune surveillance and killing via decreasing Fas expression, and can counterattack the immune system via increasing FasL expression. Fas/FasL can serve as potential targets for effective antitumor therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16273638      PMCID: PMC4436628          DOI: 10.3748/wjg.v11.i39.6125

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  15 in total

1.  Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis.

Authors:  K Okada; K Komuta; S Hashimoto; S Matsuzaki; T Kanematsu; T Koji
Journal:  Clin Cancer Res       Date:  2000-09       Impact factor: 12.531

2.  Monoclonal antibody-mediated tumor regression by induction of apoptosis.

Authors:  B C Trauth; C Klas; A M Peters; S Matzku; P Möller; W Falk; K M Debatin; P H Krammer
Journal:  Science       Date:  1989-07-21       Impact factor: 47.728

Review 3.  Positive and negative consequences of Fas/Fas ligand interactions in the antitumor response.

Authors:  Scott I Abrams
Journal:  Front Biosci       Date:  2005-01-01

Review 4.  Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack.

Authors:  Stephen Maher; Deirdre Toomey; Claire Condron; David Bouchier-Hayes
Journal:  Immunol Cell Biol       Date:  2002-04       Impact factor: 5.126

5.  Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells.

Authors:  Susanne Strand; Petra Vollmer; Lothar van den Abeelen; Daniela Gottfried; Vijay Alla; Hans Heid; Jürgen Kuball; Matthias Theobald; Peter R Galle; Dennis Strand
Journal:  Oncogene       Date:  2004-04-29       Impact factor: 9.867

6.  Expression of Fas ligand in retinoblastoma.

Authors:  Subramanian Krishnakumar; Mallikarjuna Kandalam; Adithi Mohan; Anita Iyer; Nalini Venkatesan; Jyotirmay Biswas; Mahesh Palanivelu Shanmugam
Journal:  Cancer       Date:  2004-10-01       Impact factor: 6.860

7.  Fas ligand expression in human pancreatic cancer.

Authors:  Tetsuo Ohta; Ayman Elnemr; Hirohisa Kitagawa; Masato Kayahara; Hiroyuki Takamura; Takashi Fujimura; Gen-Ichi Nishimura; Koichi Shimizu; Shuang-Qin Yi; Koichi Miwa
Journal:  Oncol Rep       Date:  2004-10       Impact factor: 3.906

Review 8.  The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy.

Authors:  Ryungsa Kim; Manabu Emi; Kazuaki Tanabe; Yoko Uchida; Tetsuya Toge
Journal:  Cancer       Date:  2004-06-01       Impact factor: 6.860

9.  Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation.

Authors:  F G Perabo; S Kamp; D Schmidt; H Lindner; G Steiner; R H Mattes; A Wirger; K Pegelow; P Albers; E C Kohn; A von Ruecker; S C Mueller
Journal:  Br J Cancer       Date:  2001-05-18       Impact factor: 7.640

10.  Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression.

Authors:  A Houston; M W Bennett; G C O'Sullivan; F Shanahan; J O'Connell
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

View more
  9 in total

Review 1.  Targeting cell death signaling in colorectal cancer: current strategies and future perspectives.

Authors:  Bruno Christian Koehler; Dirk Jäger; Henning Schulze-Bergkamen
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

2.  Cytotoxic T Cells and Granzyme B Associated with Improved Colorectal Cancer Survival in a Prospective Cohort of Older Women.

Authors:  Anna E Prizment; Robert A Vierkant; Thomas C Smyrk; Lori S Tillmans; Heather H Nelson; Charles F Lynch; Thomas Pengo; Stephen N Thibodeau; Timothy R Church; James R Cerhan; Kristin E Anderson; Paul J Limburg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-12-15       Impact factor: 4.254

Review 3.  Colon cancer and the immune system: the role of tumor invading T cells.

Authors:  Maximilian Waldner; Carl-C Schimanski; Markus-F Neurath
Journal:  World J Gastroenterol       Date:  2006-12-07       Impact factor: 5.742

4.  Clinical significance of Fas and FasL protein expression in gastric carcinoma and local lymph node tissues.

Authors:  Qian Li; Jie Peng; Xin-Hua Li; Ting Liu; Qing-Chun Liang; Gui-Ying Zhang
Journal:  World J Gastroenterol       Date:  2010-03-14       Impact factor: 5.742

5.  Significance of Fas and FasL protein expression in cardiac carcinoma and local lymph node tissues.

Authors:  Yin Li; Da-Fu Xu; Dong Jiang; Jun Zhao; Jin-Feng Ge; Shi-Ying Zheng
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

6.  CD4 T-cell immune stimulation of HER2 + breast cancer cells alters response to trastuzumab in vitro.

Authors:  Patrick N Song; Ameer Mansur; Kari J Dugger; Tessa R Davis; Grant Howard; Thomas E Yankeelov; Anna G Sorace
Journal:  Cancer Cell Int       Date:  2020-11-10       Impact factor: 5.722

7.  In vivo Effects in Melanoma of ROCK Inhibition-Induced FasL Overexpression.

Authors:  Iotefa Teiti; Bertrand Florie; Christine Pich; Rémi Gence; Isabelle Lajoie-Mazenc; Philippe Rochaix; Gilles Favre; Anne-Françoise Tilkin-Mariamé
Journal:  Front Oncol       Date:  2015-07-14       Impact factor: 6.244

8.  Combination Treatment with Sublethal Ionizing Radiation and the Proteasome Inhibitor, Bortezomib, Enhances Death-Receptor Mediated Apoptosis and Anti-Tumor Immune Attack.

Authors:  Ercan Cacan; Alexander M Spring; Anita Kumari; Susanna F Greer; Charlie Garnett-Benson
Journal:  Int J Mol Sci       Date:  2015-12-21       Impact factor: 5.923

Review 9.  Colorectal cancer (CRC) as a multifactorial disease and its causal correlations with multiple signaling pathways.

Authors:  Mao-Lin Wan; Yu Wang; Zhi Zeng; Bo Deng; Bi-Sheng Zhu; Ting Cao; Yu-Kun Li; Jiao Xiao; Qi Han; Qing Wu
Journal:  Biosci Rep       Date:  2020-03-27       Impact factor: 3.840

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.